Effects of online complex post-traumatic stress disorder treatment in women survivors of intimate partner violence with post-traumatic stress disorder

Effects of online complex post-traumatic stress disorder treatment in women survivors of intimate partner violence with post-traumatic stress disorder (PTSD) on their symptomatology of classic PTSD and complex PTSD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN99438057

Enrollment

Registered

2021-04-07

Start date

2020-03-01

Completion date

Unknown

Last updated

2023-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex PTSD in women survivors of intimate partner violence Mental and Behavioural Disorders Post-traumatic stress disorder

Interventions

Current interventions as of 14/07/2022: The intervention will be applied in a group format, online, consisting of 24 sessions. The sample will be composed of 60 women

Cloitre, 2020), which consists of two phases. This Complex PTSD intervention will be implemented over 24 sessions delivered in 24 weeks. The control group (PTSD treatment) will receiv

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women who have experienced violence (exclusively psychological or psychological and physical) perpetrated by their partners/ex-partners 2. At least 18 years old 3. Diagnosed with complex Post-traumatic Stress Disorder (C-PTSD) according to ICD-11 criteria

Exclusion criteria

Exclusion criteria: 1. Illiteracy 2. Difficulties in completing written tests 3. Altered mental state 4. Requiring recent admission to hospital or intensive treatment for a psychological disorder

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 14/07/2022: 1. Symptoms of PTSD measured using the Escala de Gravedad de Síntomas del Trastorno de Estrés Postraumático según el DSM-5: versión forense (EGS-F) at baseline, session 4, session 8, session 12, session 18, session 24, and 6 months follow-up 2. Symptoms of PTSD and complex PTSD measured using the International Trauma Questionnaire (ITQ) at baseline, 3 months and 6 months follow-up _____ Previous primary outcome measure: 1. Symptoms of PTSD measured using the Escala de Gravedad de Síntomas del Trastorno de Estrés Postraumático según el DSM-5: versión forense (EGS-F) at baseline, session 4, session 8, session 12, and 6 months follow-up 2. Symptoms of PTSD and complex PTSD measured using the International Trauma Questionnaire (ITQ) at baseline, 3 months and 6 months follow-up	—

Measure

Time frame

Current primary outcome measure as of 14/07/2022: 1. Symptoms of PTSD measured using the Escala de Gravedad de Síntomas del Trastorno de Estrés Postraumático según el DSM-5: versión forense (EGS-F) at baseline, session 4, session 8, session 12, session 18, session 24, and 6 months follow-up 2. Symptoms of PTSD and complex PTSD measured using the International Trauma Questionnaire (ITQ) at baseline, 3 months and 6 months follow-up _____ Previous primary outcome measure: 1. Symptoms of PTSD measured using the Escala de Gravedad de Síntomas del Trastorno de Estrés Postraumático según el DSM-5: versión forense (EGS-F) at baseline, session 4, session 8, session 12, and 6 months follow-up 2. Symptoms of PTSD and complex PTSD measured using the International Trauma Questionnaire (ITQ) at baseline, 3 months and 6 months follow-up

—

Secondary

Measure	Time frame
1. Sociodemographic characteristics measured using a survey with questions developed by the study team at baseline 2. Exposure to violence measured using a survey with questions developed by the study team at baseline, 3 months and 6 months follow-up 3. Intimate partner violence experiences measured using the Composite Abuse Scale (Revised)-Short Form (CASR-SF) at baseline, 3 months and 6 months follow-up 4. Resilience measured using the Connor-Davidson resilience scale (CD-RISC) at baseline, 3 months and 6 months follow-up. 5. Emotion regulation measured using the Emotion regulation questionnaire (ERQ) at baseline, session 4, session 8, session 12, and 6 months follow-up. 6. Negative self-perception measured using the Rosenberg self-esteem scale (RSE) at baseline, session 4, session 8, session 12, and 6-months follow-up 7. Difficulty with relationships and social isolation measured using the Revised UCLA Loneliness Scale at baseline, session 4, session 8, session 12, and 6-months follow-up 8. Perceived change measured using the Perceived Change Index at the end of each session 9. Retention rates assessed as the number of participants who consent to participate that remain in the trial by 3- and 6-month follow-up	—

Measure

Time frame

1. Sociodemographic characteristics measured using a survey with questions developed by the study team at baseline 2. Exposure to violence measured using a survey with questions developed by the study team at baseline, 3 months and 6 months follow-up 3. Intimate partner violence experiences measured using the Composite Abuse Scale (Revised)-Short Form (CASR-SF) at baseline, 3 months and 6 months follow-up 4. Resilience measured using the Connor-Davidson resilience scale (CD-RISC) at baseline, 3 months and 6 months follow-up. 5. Emotion regulation measured using the Emotion regulation questionnaire (ERQ) at baseline, session 4, session 8, session 12, and 6 months follow-up. 6. Negative self-perception measured using the Rosenberg self-esteem scale (RSE) at baseline, session 4, session 8, session 12, and 6-months follow-up 7. Difficulty with relationships and social isolation measured using the Revised UCLA Loneliness Scale at baseline, session 4, session 8, session 12, and 6-months follow-up 8. Perceived change measured using the Perceived Change Index at the end of each session 9. Retention rates assessed as the number of participants who consent to participate that remain in the trial by 3- and 6-month follow-up

—

Countries

Spain

Contacts

Public ContactCarmen Fernández-Fillol

carmenffillol@ugr.es+249 (0)958245168

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026